chevron_leftBack
As of 5 June 2026, Tiziana Life Sciences Ltd. has a market cap of $160.81M USD, ranking #22460 globally and #521 in the United Kingdom.
It ranks #2023 in the Healthcare sector, and #727 in the Drug Manufacturers - General industry.
Key Stats
Market Cap
$160.81MUSD
Enterprise Value
$154.3MUSD
EBITDA (TTM)
-$18.46MUSD
Net Income (TTM)
-$12.84MUSD
PB Ratio
16.3
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Ivor Elrifi
open_in_new
Employees
9
Founded
2013
IPO
24 Mar 2000
Website
tizianalifesciences.com
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| 0.8% | 1.6% | 1.6% | -22% | -35% | -3.8% |
News
Loading...
TLSA Analyst Forecasts
Loading...
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
TLSA
Tiziana Life Sciences Ltd Ordinary Shares
ISIN: BMG889121031
Shares Out.:
Shares Outstanding:
118.852M1
Shares Float:
60.904M2
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
NQ:
NASDAQ:
BA:
Barron's:
MS:
Morningstar:
|
1.26 USD |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About Tiziana Life Sciences Ltd.
Tiziana Life Sciences Ltd, a biotechnology company, engages in the development of transformative therapies for neurodegenerative and lung diseases in the United States. The company’s lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for use in the treatment of Crohn’s, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It is also developing TZLS-501, a fully human mAb targeting the IL-6 receptor for use in the treatment of inflammatory and oncology indications. Tiziana Life Sciences Ltd was incorporated in 1998 and is headquartered in London, the United Kingdom.
Similar Companies
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
LSE: AZN
|
$289.43B
180K%
215.59B GBP
|
27.6
|
|
LSE: GSK
|
$108.68B
67K%
80.96B GBP
|
14.6
|
|
LSE: HLN
|
$41.91B
26K%
31.22B GBP
|
19.0
|
|
NASDAQ: ROIV
|
$19.69B
12K%
|
-
|
|
NASDAQ: CNTA
|
$6.1B
4K%
|
-
|
|
NASDAQ: KNSA
|
$4.07B
2K%
|
58.4
|
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
NYSE: LLY
|
$761.68B
474K%
|
38.1
|
|
NYSE: JNJ
|
$547.28B
340K%
|
26.4
|
|
NYSE: ABBV
|
$360.63B
224K%
|
97.4
|
|
SIX: RO
|
$324.68B
202K%
256.25B CHF
|
19.9
|
|
SIX: NOVN
|
$277.35B
172K%
218.9B CHF
|
20.5
|
|
NYSE: MRK
|
$274.03B
170K%
|
15.1
|
chevron_leftBack